

Paris, October 10, 2018

Denis Gestin appointed as Chairman of Holistick Medical – first startup funded by Truffle Capital's *BioMedTech Crossover Fund*

Holistick Medical (Holistick) is developing a device to treat common heart defects, including patent foramen ovale (PFO), which is linked with occurrence of strokes in young individuals

Paris, October 10, 2018 – Truffle Capital, an independent venture capital firm focused on creating and financing start-ups with disruptive technologies in life sciences and information technology, today announces the appointment of Denis Gestin, 54, as Chairman of the Board of Directors of Holistick, the first startup company funded by Truffle Capital's new *BioMedTech Crossover fund*.

"We're extremely pleased to welcome Denis Gestin as Chairman of the Board of Holistick. His extensive management experience and track record in successfully launching global medical technologies, including in cardiology, will go a long way for the development of the company and its future commercial success", said Philippe Pouletty, MD, co-founder and CEO of Truffle Capital and his Truffle partners Antoine Pau, Alain Chevallier, and Vincent Gardès.



Denis Gestin, whose expertise in the field is recognized worldwide, has over 30 years of experience in the management and commercial development of medical technologies companies. Prior to joining Holistick's Board of Directors, he had been serving as Senior Vice President of Global Commercial Integration at Abbott Laboratories, since January 2017. Beforehand, Mr. Gestin worked for more than 20 years at St. Jude Medical, where he held various executive positions in Europe, the Middle East, Africa, Canada and, more recently, as President of the International Division (OUS), up until 2017. Mr. Gestin began his career with Ela Medical Inc. (Livanova), where he worked in marketing and business development from 1988 to 1997. A graduate of EDC Paris Business School, Mr. Gestin is also a member of the Board of Directors of the Swedish company Acarix.

About Holistick Medical (Holistick)

Holistick is developing a device to treat common heart defects, including patent foramen ovale (PFO), a septal defect that causes a blood flow between the two atria and is observed in one out of four individuals. Three clinical studies recently published in the *New England Journal of Medicine* show that, in patients under 60, PFO closure significantly reduces the risk of recurring stroke. These studies led the FDA to approve two devices in this indication. Unlike current metallic implants, Holistick uses flexible and bioresorbable materials, allowing for an atraumatic PFO closure that respects the integrity of the cardiac septum. Holistick owns the exclusive, global licensing rights for this heart-defect repair technology, jointly developed by Harvard and the Massachusetts Institute of Technology (MIT)ⁱ. Holistick was created by Truffle Capital, with the firm's new BioMedTech fund.

About Truffle Capital

Founded in 2001, Truffle Capital is an independent, European venture capital firm focused on disruptive technologies in life sciences (BioTech and MedTech) and IT (FinTech and InsurTech). Truffle Capital aims to support the creation and growth of young innovative companies with the potential to become tomorrow's market leaders. Chaired by Patrick Kron, alongside the company's founders and CEOs, Philippe Pouletty, M.D. and Bernard-Louis Roques, Truffle Capital currently manages € 450 M (close to €1 billion since inception) and has supported over 80 companies since its creation, in the digital technologies and life sciences sectors. At the end of 2017, Truffle Capital successfully completed the first close of its two new institutional funds, Truffle Financial Innovation Fund and Truffle BioMedTech Crossover Fund, as well as the first close of a fund dedicated to the French Reserve Fund (Fonds de Réserve pour les Retraites ou FRR).

Find out more: www.truffle.com – Twitter: [@trufflecapital](https://twitter.com/trufflecapital)

Press contact

ALIZE RP

Caroline Carmagnol and Aurore Gangloff

truffle@alizerp.com

+33 (0) 1 44 54 36 62 / +33 (0) 6 64 18 99 59

¹ Ref. PR of March 15th 2018 : http://truffle.com/wp-content/uploads/2018/03/CP_Truffle_Harvard-Holistick_.pdf